BamSEC and AlphaSense Join Forces
Learn More

Eton Pharmaceuticals Inc. – Material Contracts

NASDAQ: ETON    
Share price (6/29/26): $36.73    
Market cap (6/29/26): $1.006 billion
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 10-Q 38 pages Certain Information Has Been Excluded From the Exhibit Because It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential Exclusive License Agreement
12/34/56
EX-10.1
from 8-K 103 pages Agreement
12/34/56
EX-10.4
from 10-Q 6 pages November 6, 2024 (Amended June 30, 2025 for Change in Severance Provision) Re: Employment Terms
12/34/56
EX-10.3
from 10-Q 6 pages March 18, 2022 (Amended June 30, 2025 for Change in Severance Provision) Re: Employment Terms
12/34/56
EX-10.2
from 10-Q 6 pages August 2, 2017 David Krempa (Amended June 30, 2025 for Change in Severance Position) Re: Employment Terms
12/34/56
EX-10.1
from 10-Q 7 pages May 14, 2017 (As Amended June 30, 2025 for Change in Severance Provisions) Re: Employment Terms 1. Effectiveness
12/34/56
EX-10.14
from 10-K 21 pages Licence Agreement
12/34/56
EX-10.11
from 10-K 48 pages Certain Information Has Been Excluded From This Exhibit Because It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential
12/34/56
EX-10.1
from 8-K 29 pages Certain Information Has Been Redacted From This Exhibit Because It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential Asset Purchase Agreement
12/34/56
EX-10.1
from 8-K 12 pages Form of Securities Purchase Agreement
12/34/56
EX-10.2
from 10-Q 19 pages This Warrant and the Securities Issued Hereunder Have Not Been Registered Under the Securities Act of 1933, as Amended (The “Securities Act”), or Any Other Securities Laws and May Not Be Offered for Sale, Sold, Transferred, Pledged or Hypothecated in the Absence of (1) an Effective Registration Statement Covering Such Securities Under the Securities Act and Any Other Applicable Securities Laws, or (2) an Exemption From Registration Under Such Securities Laws. Second Amended and Restated Eton Pharmaceuticals, Inc. Warrant for Shares of Common Stock September 30, 2024
12/34/56
EX-10.6
from 10-K 12 pages Material contract
12/34/56
EX-10.1
from 10-Q 42 pages Note: Certain Identified Information Has Been Excluded From This Exhibit Because It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. Omitted Information Is Indicated With the Following: [*] Asset Purchase Agreement
12/34/56
EX-10.11
from 10-K 23 pages Eton Pharmaceuticals, Inc. 2018 Equity Incentive Plan Last Amended January 2021
12/34/56
EX-10.1
from 8-K 4 pages Material contract
12/34/56
EX-10.3
from 8-K 50 pages Material contract
12/34/56
EX-10.2
from 8-K 34 pages Material contract
12/34/56
EX-10.1
from 8-K 10 pages Material contract
12/34/56
EX-10.14
from 10-K 114 pages Material contract
12/34/56
EX-10.1
from 10-Q 23 pages Certain Information Identified by Bracketed Asterisks ([ * * * ]) Has Been Omitted From This Exhibit Because It Is Both Not Material and Would Be Competitively Harmful if Publicly Disclosed. Exclusive License and Product Development Agreement
12/34/56